Venkatasubramanian Baskararajan, MD
Psychiatry · Hattiesburg, MSNPI 1407052228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 469 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$624
- Neurocrine Biosciences, Inc.$524
- Lundbeck LLC$416
- plus $2K from 10 others
What the payments were for
- Food & beverage$6,83499%
- Education$831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 125 | $1,351 |
| Alkermes, Inc. | 71 | $1,138 |
| Johnson & Johnson | 75 | $1,063 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $624 |
| Neurocrine Biosciences, Inc. | 30 | $524 |
| Lundbeck LLC | 24 | $416 |
| E.r. Squibb & Sons, L.L.C. | 20 | $356 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $333 |
| Otsuka America Pharmaceutical, Inc. | 18 | $324 |
| Teva Pharmaceuticals USA, Inc. | 16 | $250 |
| Indivior Inc. | 6 | $148 |
| Sunovion Pharmaceuticals Inc. | 12 | $139 |
| Axsome Therapeutics, Inc. | 6 | $116 |
| Vanda Pharmaceuticals Inc. | 4 | $101 |
| Shire North American Group Inc | 2 | $31 |
| Neuronetics, Inc. | 1 | $2 |
How this compares
$6,917 in reported general payments places this provider in the 90th percentile of 219 psychiatry providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 70 | $628,900 |
| AristadaAripiprazole Lauroxil | 156 | $463,756 |
| AustedoDeutetrabenazine | 46 | $303,468 |
| Invega SustennaPaliperidone Palmitate | 94 | $267,665 |
| IngrezzaValbenazine Tosylate | 20 | $162,042 |
| VraylarCariprazine Hcl | 97 | $136,369 |
| Abilify MaintenaAripiprazole | 26 | $67,331 |
| RexultiBrexpiprazole | 31 | $58,987 |
| PerserisRisperidone | 17 | $43,745 |
| CaplytaLumateperone Tosylate | 27 | $42,014 |
| TrintellixVortioxetine Hydrobromide | 58 | $31,110 |
| Clozapine | 201 | $22,046 |
| VivitrolNaltrexone Microspheres | 12 | $17,417 |
| Haloperidol Decanoate | 180 | $11,472 |
| Bupropion XlBupropion Hcl | 537 | $7,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,063 | $896,565164 claims |
| Alkermes, Inc.Aristada, Vivitrol | $1,138 | $481,173168 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $250 | $303,46846 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $524 | $162,04220 claims |
| AbbVieVraylar | $1,351 | $136,36997 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $324 | $126,31857 claims |
| Indivior Inc.Perseris | $148 | $43,74517 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $624 | $42,01427 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $333 | $31,11058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 psychiatry providers in Mississippi.
Other psychiatry in Hattiesburg
- Kevin HoHattiesburg$6K
- Maxie GordonClinton$1.3M
- Kurt BuechlerRidgeland$1.1M
- Chasity TorrenceWhitfield$834K
- Jon JacksonJackson$834K
- John NortonJackson$173K
- Amy MillerSaltillo$82K
- Clyde GlennRidgeland$68K
- Krishan GuptaJackson$26K
- Joseph KwentusFlowood$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.